Genetic diagnostics of ultra-rare diseases: Large multicenter study identifies 34 new genetic diseases

The majority of rare diseases have a genetic cause. The underlying genetic alteration can be found more and more easily, for example by means of exome sequencing (ES), leading to a molecular genetic diagnosis. ES is an examination of all sections of our genetic material (DNA) that code for proteins. As part of a Germany-wide multicenter study, ES data was collected from 1,577 patients and systematically evaluated.

Background Research:

Genetic diseases are disorders caused by abnormalities in DNA and can be divided into three categories: single-gene, chromosomal, and complex. Single-gene disorders like cystic fibrosis occur due to defects in a single gene, chromosomal disorders result from inconsistencies with entire chromosomes or part of chromosomes (such as Down Syndrome), and complex genetic conditions result from a combination of environmental factors along with slight variations in genes.

Exome sequencing (ES) is a technique used for sequencing all of the protein-coding sections of genes in a genome known as exomes. An exome makes up about 1% of the genome but contains around 85% of known disease-related variants, making this method an efficient way to identify potential genetic causes relative to whole-genome sequencing methods.

FAQ:

Q1: What exactly is this study about?
A: This study focuses on detecting new ultra-rare diseases through exome sequencing (ES). ES allows us to examine all sections of our genetic material that codes for proteins – identifying rare disease-causing genetic mutations.

Q2: How many patients were involved in the multicenter study?
A: A total number of 1577 patients were systematically evaluated throughout Germany as part of this study.

Q3: What is Exome Sequencing (ES)?
A: ES is an advanced technology used for analysing various parts or exons that code for proteins within our DNA. This technique has proved beneficial towards mapping out molecular genetics leading towards specific diagnoses.

Q4: How many new genetic diseases have been identified through this research?
A: The large multicenter study has succeeded in identifying 34 new ultra-rare genetic diseases using molecular genetics techniques like ES.

Q5: Why are these discoveries significant?
A:The identification of these syndromes expands our understanding on tiny proportions among broader range disorders. Furthermore, it paves way towards more comprehensive diagnostic services benefitting those rare patients suffering from such diseases.

Q6: What are the implications for people suffering from these ultra-rare diseases?
A: These findings provide an opportunity for potentially more accurate diagnoses, which can lead to targeted therapeutic approaches and better management of the diseases through personalized medicine.

Q7: Where can I find more information about this research?
A: More detailed information is available on the idw-online.de website. You can follow this link to access the press release directly – http://idw-online.de/de/news837278

Originamitteilung:

The majority of rare diseases have a genetic cause. The underlying genetic alteration can be found more and more easily, for example by means of exome sequencing (ES), leading to a molecular genetic diagnosis. ES is an examination of all sections of our genetic material (DNA) that code for proteins. As part of a Germany-wide multicenter study, ES data was collected from 1,577 patients and systematically evaluated.

share this recipe:
Facebook
Twitter
Pinterest

Weitere spannende Artikel

sphin-X konstituiert sich als eingetragener Verein und hat seinen Vorstand gewählt

Berlin. Die Datenraum-Initiative sphin-X hat einen wichtigen Projekt-Meilenstein erreicht und den Verein sphin-X e. V. offiziell gegründet. Im Rahmen der Gründungsversammlung mit Mitgliedsunternehmen, -vereinen und -verbänden aus der Gesundheitswirtschaft wurde auch der Vorstand gewählt.
Zweck des Vereins ist die Förderung einer gemeinwohlorientierten Nutzung von Daten in der Gesundheitsbranche. Mit der Vereinsgründung optimiert das Projektteam von sphin-X die Koordination seiner mittlerweile mehr als 50 beteiligten Partner.

Read More

MedLabPortal now also on BlueSky, LinkedIn and X

As the official portal of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL), MedLabPortal is committed to freedom of information – and has also been offering its content on the DGKL’s social media channels on BlueSky, LinkedIn and X (formerly Twitter) since the beginning of November. In this way, users can access the content of the special interest website across all platforms.

Read More